<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SOMA- carisoprodol tablet </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"> These highlights do not include all the information needed to use SOMA safely and effectively. See full prescribing information for SOMA.<br><br>SOMA (carisoprodol) Tablets for Oral use <br>Initial U.S. Approval: 1959  </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions, Sedation <a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">(5.1)</a> 10/2009 </p>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, Withdrawal, and Abuse <a href="#i4i_section_id_e860e381-5e0a-4ccb-84b9-9ba253d8dbf5">(5.2)</a> 10/2009 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">SOMA is indicated for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions. <a href="#i4i_indications_id_f12bf9e5-2d61-4a9f-b7b3-1f90f3ffc1f5">(1)</a><br><br>Important Limitations: </p>
<ul>
<li>Should only be used for acute treatment periods up to two or three weeks <a href="#i4i_indications_id_f12bf9e5-2d61-4a9f-b7b3-1f90f3ffc1f5">(1)</a>
</li>
<li>Not recommended in pediatric patients less than 16 years of age <a href="#i4i_pediatric_use_id_9a0632a4-b8d9-4182-851d-7bb5e7becab2">(8.4)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>Recommended dose is 250 mg to 350 mg three times a day and at bedtime. <a href="#i4i_dosage_admin_id_2239577b-1b14-4b57-8cab-32cb389a0d7a">(2)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 250 mg, 350 mg <a href="#i4i_dosage_form_strength_id_24798518-363a-4411-b70b-25a42a43b870">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">Acute intermittent porphyria</span> <a href="#i4i_contraindications_id_e94db740-86a3-4767-acc2-05dce6138f78">(4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to a carbamate such as meprobamate <a href="#i4i_contraindications_id_e94db740-86a3-4767-acc2-05dce6138f78">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery <a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">(5.1)</a>
</li>
<li>Additive sedative effects when used with other CNS depressants including alcohol <a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">(5.1)</a>
</li>
<li>Cases of <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, Withdrawal, and Abuse <a href="#i4i_section_id_e860e381-5e0a-4ccb-84b9-9ba253d8dbf5"> (5.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <a href="#i4i_section_id_a6afd3c2-9eb6-4d3a-9122-0f227bc1f4cd"> (5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt; 2%) are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <a href="#i4i_section_id_1ea75d76-43ae-45ca-8635-dba00c7a885f">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span>. </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects (<a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa"> 5.1</a> and <a href="#i4i_section_id_a8ff2b52-bca9-4f29-89ca-b77d1bd2a1b5"> 7.1</a>) </li></ul></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Sedation</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, Withdrawal, and Abuse</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS Depressants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C19 Inhibitors and Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Patients with Reduced CYP2C19 Activity</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Sedation</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Avoidance of Alcohol and Other CNS Depressants</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 SOMA Should Only Be Used for Short-Term Treatment</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f12bf9e5-2d61-4a9f-b7b3-1f90f3ffc1f5"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">SOMA is indicated for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions in adults.<br> SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [<span class="Italics"><a href="#i4i_dosage_admin_id_2239577b-1b14-4b57-8cab-32cb389a0d7a">see Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2239577b-1b14-4b57-8cab-32cb389a0d7a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of SOMA is 250 mg to 350 mg three times a day and at bedtime. The recommended maximum duration of SOMA use is up to two or three weeks.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_24798518-363a-4411-b70b-25a42a43b870"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">250mg Tablets: round, convex, white tablets, inscribed with SOMA 250</p>
<p>350mg Tablets: round, convex, white tablets, inscribed with SOMA 350</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e94db740-86a3-4767-acc2-05dce6138f78"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">SOMA is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> or a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to a carbamate such as meprobamate.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f98ce802-f4f7-4698-a232-6c48823511b5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Sedation</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SOMA has sedative properties (in the <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> trials, 13% to 17% of patients who received SOMA experienced sedation compared to 6% of patients who received placebo) [<span class="Italics"><a href="#i4i_section_id_1ea75d76-43ae-45ca-8635-dba00c7a885f">see ADVERSE REACTIONS (6.1)</a></span>] and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span> associated with the use of SOMA.</span></p>
<p>Since the sedative effects of SOMA and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e860e381-5e0a-4ccb-84b9-9ba253d8dbf5"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, Withdrawal, and Abuse</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In the postmarketing experience with SOMA, cases of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, and abuse have been reported with prolonged use. Most cases of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, and abuse occurred in patients who have had a history of addiction or who used SOMA in combination with other drugs with abuse potential. However, there have been post-marketing adverse event reports of SOMA-associated abuse when used without other drugs with abuse potential. Withdrawal symptoms have been reported following abrupt cessation after prolonged use. To reduce the chance of SOMA <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, or abuse, SOMA should be used with caution in addiction-prone patients and in patients taking other CNS depressants including alcohol, and SOMA should not be used more than two to three weeks for the relief of acute musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</span></p>
<p>SOMA, and one of its metabolites, meprobamate (a controlled substance), may cause <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> [<span class="Italics"><a href="#i4i_pharmacokinetics_id_ed325820-b96a-4eae-b2e6-b9f1ec138b5e">see Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6afd3c2-9eb6-4d3a-9122-0f227bc1f4cd"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients who received SOMA. Most of these cases have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol) [<span class="Italics"><a href="#i4i_overdosage_id_af036058-4835-42b9-a288-ea0543033135">see Overdosage (10)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a996ce6f-cb18-406f-9d28-9f1c52119fd0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ea75d76-43ae-45ca-8635-dba00c7a885f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.</p>
<p>The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> [<span class="Italics"><a href="#i4i_clinical_studies_id_85add845-afc8-4d9e-84b4-bdea0d9f19ad">see Clinical Studies (14)</a></span>]. In these studies, patients were treated with 250 mg of SOMA, 350 mg of SOMA, or placebo three times a day and at bedtime for seven days. The mean age was about 41 years old with 54% females and 46% males and 74 % Caucasian, 16 % Black, 9% Asian, and 2% other.</p>
<p>There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and there were no serious adverse reactions in these two trials. In these two studies, 2.7%, 2%, and 5.4%, of patients treated with placebo, 250 mg of SOMA, and 350 mg of SOMA, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo, 250 mg of SOMA, and 350 mg of SOMA, respectively, discontinued due to central nervous system adverse reactions.</p>
<p>Table 1 displays adverse reactions reported with frequencies greater than 2% and more frequently than placebo in patients treated with SOMA in the two trials described above.</p>
<a name="id_0770f28b-539d-405b-bef1-625a0b7f40a8"></a><table width="0.000">
<caption><span>Table 1. Patients with Adverse Reactions in Controlled Studies</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo<br></span><span class="Bold">(n=560)<br></span><span class="Bold">n (%)</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">SOMA 250 mg<br></span><span class="Bold">(n=548)<br></span><span class="Bold">n (%)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">SOMA 350 mg<br></span><span class="Bold">(n=279)<br></span><span class="Bold"> n (%)</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td align="center" valign="top">31 (6)</td>
<td align="center" valign="top">73 (13)</td>
<td align="center" valign="top">47 (17)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">11 (2)</td>
<td align="center" valign="top">43 (8)</td>
<td align="center" valign="top">19 (7)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">11 (2)</td>
<td align="center" valign="top">26 (5)</td>
<td align="center" valign="top">9 (3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c723422-e4b0-476c-80e2-e2d0fc3d7b88"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following events have been reported during postapproval use of SOMA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> [<span class="Italics"><a href="#i4i_overdosage_id_af036058-4835-42b9-a288-ea0543033135">see Overdosage (10)</a></span>].<br><span class="Italics">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, depressive reactions, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [<span class="Italics"><a href="#i4i_overdosage_id_af036058-4835-42b9-a288-ea0543033135">see Overdosage (10)</a></span>].<br><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>.<br><span class="Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3cb745a3-40d4-421d-9bf4-e5d98991332d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8ff2b52-bca9-4f29-89ca-b77d1bd2a1b5"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CNS Depressants</h2>
<p class="First">The sedative effects of SOMA and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of SOMA and meprobamate, a metabolite of SOMA, is not recommended [<span class="Italics"><a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">see Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_167c59a9-e98f-4ace-8ef1-18db5344291a"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C19 Inhibitors and Inducers</h2>
<p class="First">Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate [<span class="Italics"><a href="#i4i_pharmacokinetics_id_ed325820-b96a-4eae-b2e6-b9f1ec138b5e">see Clinical Pharmacology (12.3)</a></span> ]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with SOMA could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John’s Wort, with SOMA could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of SOMA is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_96d1cf69-753a-4781-abb5-8e2c5513af57"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5f93bfa5-759f-46b4-b4dd-92e85e411c44"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">There are no data on the use of SOMA during human pregnancy. Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations.</p>
<p><span class="Italics">Teratogenic effects:</span> Animal studies have not adequately evaluated the teratogenic effects of carisoprodol. There was no increase in the incidence of congenital malformations noted in reproductive studies in rats, rabbits, and mice treated with meprobamate. Retrospective, post-marketing studies of meprobamate during human pregnancy were equivocal for demonstrating an increased risk of congenital malformations following first trimester exposure. Across studies that indicated an increased risk, the types of malformations were inconsistent.</p>
<p><span class="Italics"> Nonteratogenic effects:</span> In animal studies, carisoprodol reduced fetal weights, postnatal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and postnatal survival at maternal doses equivalent to 1-1.5 times the human dose (based on a body surface area comparison). Rats exposed to meprobamate in-utero showed behavioral alterations that persisted into adulthood. For children exposed to meprobamate in-utero, one study found no adverse effects on mental or motor development or IQ scores. SOMA should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_d76473f3-e77e-4883-8124-dee2b891e737"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is no information about the effects of SOMA on the mother and the fetus during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_a9ea2247-17fe-43e7-a2ce-9e68fc6040f5"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Very limited data in humans show that SOMA is present in breast milk and may reach concentrations two to four times the maternal plasma concentrations. In one case report, a breast-fed infant received about 4-6% of the maternal daily dose through breast milk and experienced no adverse effects. However, milk production was inadequate and the baby was supplemented with formula. In lactation studies in mice, female pup survival and pup weight at weaning were decreased. This information suggests that maternal use of SOMA may lead to reduced or less effective infant feeding (due to sedation) and/or decreased milk production. Caution should be exercised when SOMA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9a0632a4-b8d9-4182-851d-7bb5e7becab2"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of SOMA in pediatric patients less than 16 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7131ee19-98e3-47df-8d48-cd27994c1001"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of SOMA in patients over 65 years old have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17d223a0-a1f5-4456-88c7-d5544aab0cde"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The safety and pharmacokinetics of SOMA in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been evaluated. Since SOMA is excreted by the kidney, caution should be exercised if SOMA is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Carisoprodol is dialyzable by hemodialysis and peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d95b355a-cc71-4ef4-b7e8-795dd1403a60"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The safety and pharmacokinetics of SOMA in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated. Since SOMA is metabolized in the liver, caution should be exercised if SOMA is administered to patients with impaired hepatic function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6a0cb1c-5315-4789-bf02-ebf8417b01d6"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Patients with Reduced CYP2C19 Activity</h2>
<p class="First">Patients with reduced CYP2C19 activity have higher exposure to carisoprodol. Therefore, caution should be exercised in administration of SOMA to these patients [<span class="Italics"><a href="#i4i_pharmacokinetics_id_ed325820-b96a-4eae-b2e6-b9f1ec138b5e"> see Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_64721e2a-d2df-40c6-9531-779295594810"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">SOMA is not a controlled substance [<span class="Italics"><a href="#i4i_section_id_e860e381-5e0a-4ccb-84b9-9ba253d8dbf5">see Warnings and Precautions (5.2)</a></span> ]. Discontinuation of carisoprodol in animals or in humans after chronic administration can produce withdrawal signs, and there are published case reports of human carisoprodol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. </p>
<p><span class="Italics">In vitro</span> studies demonstrate that carisoprodol elicits barbiturate-like effects. Animal behavioral studies indicate that carisoprodol produces rewarding effects. Monkeys self administer carisoprodol. Drug discrimination studies using rats indicate that carisoprodol has positive reinforcing and discriminative effects similar to barbital, meprobamate, and chlordiazepoxide.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_af036058-4835-42b9-a288-ea0543033135"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of SOMA commonly produces <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">muscular incoordination</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have been reported with SOMA overdosage. Many of the SOMA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol). The effects of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of SOMA and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) can be additive even when one of the drugs has been taken in the recommended dosage. Fatal accidental and non-accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of SOMA have been reported alone or in combination with CNS depressants.</p>
<p><span class="Bold"> Treatment of Overdosage:</span> Basic life support measures should be instituted as dictated by the clinical presentation of the SOMA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended due to the risk of CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, which may increase the risk of <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>. Gastric lavage should be considered soon after ingestion (within one hour). Circulatory support should be administered with volume infusion and vasopressor agents if needed. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be treated with intravenous benzodiazepines and the reoccurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be treated with phenobarbital. In cases of severe <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support. </p>
<p>The following types of treatment have been used successfully with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of meprobamate, a metabolite of SOMA: activated charcoal (oral or via nasogastric tube), forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, and hemodialysis (carisoprodol is also dialyzable). Careful monitoring of urinary output is necessary and <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span> should be avoided. Observe for possible relapse due to incomplete gastric emptying and delayed absorption. For more information on the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of SOMA, <span class="Bold"> contact a Poison Control Center.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_671c2bb4-d8fb-4886-975e-540ac01e8d05"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SOMA (carisoprodol) Tablets are available as 250 mg and 350 mg round, white tablets. Carisoprodol is a white, crystalline powder, having a mild, characteristic odor and a bitter taste. It is slightly soluble in water; freely soluble in alcohol, in chloroform, and in acetone; and its solubility is practically independent of pH. Carisoprodol is present as a racemic mixture. Chemically, carisoprodol is N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate and the molecular formula is C<span class="Sub">12</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">4</span>, with a molecular weight of 260.33. The structural formula is: </p>
<p><img alt="Carisoprodol Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6543c6ba-852e-40fb-b7ec-1331b9c83656&amp;name=6543c6ba-852e-40fb-b7ec-1331b9c83656-01.jpg"></p>
<p> Other ingredients in the SOMA drug product include alginic acid, magnesium stearate, potassium sorbate, starch, and tribasic calcium phosphate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9f894f19-1b16-4fcf-8771-4d7366a8801a"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_5878f484-bc28-4e3c-8070-b8c11739fa4f"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of carisoprodol in relieving <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute painful musculoskeletal conditions has not been clearly identified. </p>
<p>In animal studies, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_2331b555-26c3-466b-aaa5-9af6b44776c4"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Carisoprodol is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscles.</p>
<p>A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties. The degree to which these properties of meprobamate contribute to the safety and efficacy of SOMA is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ed325820-b96a-4eae-b2e6-b9f1ec138b5e"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"> The pharmacokinetics of carisoprodol and its metabolite meprobamate were studied in a crossover study of 24 healthy subjects (12 male and 12 female) who received single doses of 250 mg and 350 mg SOMA (see Table 2). The exposure of carisoprodol and meprobamate was dose proportional between the 250 mg and 350 mg doses. The Cmax of meprobamate was 2.5 ± 0.5 μg/mL (mean ± SD) after administration of a single 350 mg dose of SOMA, which is approximately 30% of the Cmax of meprobamate (approximately 8 μg/mL) after administration of a single 400 mg dose of meprobamate. </p>
<a name="id_13f7b910-1f64-4694-8086-8749aa20fcef"></a><table width="0.000">
<caption><span>Table 2. Pharmacokinetic Parameters of Carisoprodol and Meprobamate (Mean ± SD, n=24)</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">250 mg SOMA</span></td>
<td align="center" valign="top"><span class="Bold"> 350 mg SOMA</span></td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top"><span class="Bold">Carisoprodol</span></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> Cmax (μg/mL)</span></td>
<td align="center" valign="top">1.2 ± 0.5</td>
<td align="center" valign="top">1.8 ± 1.0</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> AUC<span class="Sub">inf</span> (μg<span class="Sup">*</span>hr/mL)</span></td>
<td align="center" valign="top">4.5 ± 3.1</td>
<td align="center" valign="top">7.0 ± 5.0</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> Tmax (hr)</span></td>
<td align="center" valign="top">1.5 ± 0.8</td>
<td align="center" valign="top">1.7 ± 0.8</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> T<span class="Sub">1/2</span> (hr)</span></td>
<td align="center" valign="top">1.7 ± 0.5</td>
<td align="center" valign="top">2.0 ± 0.5</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top"><span class="Bold"> Meprobamate</span></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> Cmax (μg/mL)</span></td>
<td align="center" valign="top">1.8 ± 0.3</td>
<td align="center" valign="top">2.5 ± 0.5</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> AUC<span class="Sub">inf</span> (μg<span class="Sup">*</span>hr/mL)</span></td>
<td align="center" valign="top">32 ± 6.2</td>
<td align="center" valign="top">46 ± 9.0</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold"> Tmax (hr)</span></td>
<td align="center" valign="top">3.6 ± 1.7</td>
<td align="center" valign="top">4.5 ± 1.9</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><span class="Bold"> T<span class="Sub">1/2</span> (hr)</span></td>
<td align="center" valign="top">9.7 ± 1.7</td>
<td align="center" valign="top">9.6 ± 1.5</td>
</tr>
</tbody>
</table>
<p><span class="Italics"> Absorption:</span> Absolute bioavailability of carisoprodol has not been determined. The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours. Co-administration of a high-fat meal with SOMA (350 mg tablet) had no effect on the pharmacokinetics of carisoprodol. Therefore, SOMA may be administered with or without food.</p>
<p><span class="Italics"> Metabolism:</span> The major pathway of carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate. This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below). </p>
<p><span class="Italics">Elimination:</span> Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours. The half-life of meprobamate is approximately 10 hours.</p>
<p><span class="Italics"> Gender:</span> Exposure of carisoprodol is higher in female than in male subjects (approximately 30-50% on a weight adjusted basis). Overall exposure of meprobamate is comparable between female and male subjects.</p>
<p><span class="Italics"> Patients with Reduced CYP2C19 Activity:</span> SOMA should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3-5% and in Asians is approximately 15-20%.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_f5fdd90e-3317-44aa-be58-c15a2bbed2f4"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_7c559d98-6081-4435-8bf2-8753dcf550d0"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.</p>
<p>SOMA was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the <span class="Italics">in vitro</span> chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using <span class="Italics">S. typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with or without metabolizing enzymes, and was not clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay of circulating blood cells.</p>
<p>SOMA was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison. The significance of these findings for human fertility is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_85add845-afc8-4d9e-84b4-bdea0d9f19ad"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of SOMA for the relief of acute, idiopathic mechanical <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> was evaluated in two, 7-day, double blind, randomized, multicenter, placebo controlled, U.S. trials (Studies 1 and 2). Patients had to be 18 to 65 years old and had to have acute <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (≤ 3 days of duration) to be included in the trials. Patients with chronic <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; at increased risk for <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fracture</span> (e.g., history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>); with a history of spinal pathology (e.g., herniated nucleus pulposis, <span class="product-label-link" type="condition" conceptid="4167097" conceptname="Spondylolisthesis">spondylolisthesis</span> or spinal stenosis); with inflammatory <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, or with evidence of a neurologic deficit were excluded from participation. Concomitant use of analgesics (e.g., acetaminophen, NSAIDs, tramadol, opioid agonists), other muscle relaxants, botulinum toxin, sedatives (e.g., barbiturates, benzodiazepines, promethazine hydrochloride), and anti-epileptic drugs was prohibited. </p>
<p>In Study 1, patients were randomized to one of three treatment groups (i.e., SOMA 250 mg, SOMA 350 mg, or placebo) and in Study 2 patients were randomized to two treatment groups (i.e., SOMA 250 mg or placebo). In both studies, patients received study medication three times a day and at bedtime for seven days.</p>
<p>The primary endpoints were the relief from starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span> and the global impression of change, as reported by patients, on Study Day 3. Both endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome) in both studies. The primary statistical comparison was between the SOMA 250 mg and placebo groups in both studies. </p>
<p>The proportion of patients who used concomitant acetaminophen, NSAIDs, tramadol, opioid agonists, other muscle relaxants, and benzodiazepines was similar in the treatment groups. </p>
<p>The results for the primary efficacy evaluations in the acute, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span> studies are presented in Table 3.</p>
<a name="id_44a6d602-c383-4667-8131-9e451c0985a7"></a><table width="0.000">
<caption><span>Table 3. Results of the Primary Efficacy Endpoints<span class="Sup">a</span> in Studies 1 and 2</span></caption>
<col>
<col>
<col>
<col>
<col>
<tfoot>
<tr><td align="left" colspan="5" valign="top">a The primary efficacy endpoints (Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span> and Global Impression of Change) were assessed by the patients on Study Day 3. These endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome).</td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"> b Mean is the least squared mean and SE is the standard error of the mean. The ANOVA model was used for the primary statistical comparison between the SOMA 250 mg and placebo groups.</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold"> Study</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold"> Parameter</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold"> Placebo</span></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">SOMA<br></span><span class="Bold">250 mg</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">SOMA<br></span><span class="Bold">350 mg</span></p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Number of Patients</span></td>
<td align="center" valign="top">n=269</td>
<td align="center" valign="top">n=264</td>
<td align="center" valign="top">n=273</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span>, Mean (SE)<span class="Sup"> b</span></span></td>
<td align="center" valign="top">1.4 (0.1)</td>
<td align="center" valign="top">1.8 (0.1)</td>
<td align="center" valign="top">1.8 (0.1)</td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold">1</span></td>
<td align="left" valign="top">Difference between SOMA and Placebo, Mean (SE)<span class="Sup"> b</span> (95% CI)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">0.4<br> (0.2, 0.5)</td>
<td align="center" valign="top">0.4<br> (0.2, 0.6)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Global Impression of Change, Mean (SE)<span class="Sup"> b</span></span></td>
<td align="center" valign="top"> 1.9 (0.1) </td>
<td align="center" valign="top"> 2.2 (0.1) </td>
<td align="center" valign="top">2.2 (0.1)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Difference between SOMA and Placebo, Mean (SE)<span class="Sup"> b</span> (95% CI)</td>
<td align="left" valign="top"></td>
<td align="center" valign="top">0.2<br> (0.1, 0.4)</td>
<td align="center" valign="top">0.3<br> (0.1, 0.4)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Number of Patients</span></td>
<td align="center" valign="top">n=278</td>
<td align="center" valign="top">n=269</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Relief from Starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span>, Mean (SE)<span class="Sup"> b</span></span></td>
<td align="center" valign="top">1.1 (0.1)</td>
<td align="center" valign="top">1.8 (0.1)</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><span class="Bold">2</span></td>
<td align="left" valign="top">Difference between SOMA and Placebo, Mean (SE)<span class="Sup"> b</span> (95% CI)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">0.7<br> (0.5, 0.9)</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"> Global Impression of Change, Mean (SE)<span class="Sup"> b</span></span></td>
<td align="center" valign="top">1.7 (0.1) </td>
<td align="center" valign="top"> 2.2 (0.1) </td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">Difference between SOMA and Placebo, Mean (SE)<span class="Sup"> b</span> (95% CI)</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">0.5<br> (0.4, 0.7)</td>
<td align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p>Patients treated with SOMA experienced improvement in function as measured by the Roland-Morris <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Questionnaire (RMDQ) score on Days 3 and 7.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_41c33ba6-2d95-47ee-b1c4-28bf387c2139"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">250mg Tablets: round, convex, white tablets, inscribed with SOMA 250; available in bottles of 30 (NDC 21695-606-30).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_04e9e8be-b127-4ead-8076-48060491df10"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span><br>Store at controlled room temperature 20° - 25°C (68° - 77°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b0b2c737-952d-4ed5-8301-a3c717509576"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to contact their physician if they experience any adverse reactions to SOMA.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8654dd5f-ba40-4f09-9b11-7713d3b33d13"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Sedation</h2>
<p class="First">Patients should be advised that SOMA may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and has been associated with <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span>. Patients should be advised to avoid taking SOMA before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [<span class="Italics"><a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">see Warnings and Precautions (5.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f017ad20-8179-4100-a89a-745d61924379"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Avoidance of Alcohol and Other CNS Depressants</h2>
<p class="First">Patients should be advised to avoid alcoholic beverages while taking SOMA and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives [<span class="Italics"><a href="#i4i_section_id_0a3ae5bf-94d8-485a-b298-df2905724caa">see Warnings and Precautions (5.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2198cae6-b386-4bae-a01d-b7ab8252797a"></a><a name="section-16.3"></a><p></p>
<h2>17.3 SOMA Should Only Be Used for Short-Term Treatment</h2>
<p class="First">Patients should be advised that treatment with SOMA should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. In the post-marketing experience with SOMA, cases of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, and abuse have been reported with prolonged use. If the musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span>.</p>
<p>Meda Pharmaceuticals<br>Meda Pharmaceuticals Inc.<br>Somerset, New Jersey 08873-4120</p>
<p>IN-090H2-18     Rev. 10/09</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bee48896-0c6f-44d3-9d55-aabd8ce96aa9"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel – 30-count Bottle, 250 mg Tablets</span></p>
<p>NDC 21695-606-30<br>30 Tablets<br><span class="Bold">Soma </span><span class="Sup">®</span><span class="Bold"> 250 mg</span><br><span class="Bold">Carisoprodol Tablets</span></p>
<p><span class="Bold">Rx Only</span><br><span class="Bold">Rebel Distributors Corp <span class="Sup">®</span></span></p>
<p>Please see enclosed full Prescribing <br>Information.</p>
<p><span class="Bold">Dispense in tight container.<br>Store at controlled room temperature<br>20°-25°C (68°-77°F). </span></p>
<p><span class="Bold">Meda Pharmaceuticals <span class="Sup">®</span><br>Meda Pharmaceuticals Inc.</span><br>Somerset, New Jersey 08873-4120</p>
<p><img alt="Soma 250mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6543c6ba-852e-40fb-b7ec-1331b9c83656&amp;name=6543c6ba-852e-40fb-b7ec-1331b9c83656-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SOMA 		
					</strong><br><span class="contentTableReg">carisoprodol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-606(NDC:0037-2250)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARISOPRODOL</strong> (CARISOPRODOL) </td>
<td class="formItem">CARISOPRODOL</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SOMA;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-606-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011792</td>
<td class="formItem">09/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6543c6ba-852e-40fb-b7ec-1331b9c83656</div>
<div>Set id: 6543c6ba-852e-40fb-b7ec-1331b9c83656</div>
<div>Version: 1</div>
<div>Effective Time: 20101201</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
